Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy

NCT02348320 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer
Triple-Negative Breast Cancer
Triple Negative Breast Neoplasms

Interventions

BIOLOGICAL: Personalized polyepitope DNA vaccine

Sponsor

Washington University School of Medicine

Collaborators

[object Object]